• This study compared the efficacy of the injectable inactivated (TIV) and the intranasal attenuated (LAIV) influenza vaccines in healthy adults. (immunizationinfo.org)
  • Based on 78 vaccine efficacy or effectiveness (VE) data from 49 studies and 1,984,241 SARS-CoV-2 sequences collected from 31 regions, we analyzed the relationship between genetic distance (GD) of circulating viruses against the vaccine strain and VE against symptomatic infection. (nature.com)
  • ACIP had withdrawn its recommendation for use of LAIV during the last two influenza seasons due to data indicating greatly decreased efficacy of the H1N1 component of the live vaccine. (immunize.org)
  • I'll go over the safety and efficacy of the Janssen COVID-19 vaccine. (cdc.gov)
  • So I'll just go over a quick summary of the available evidence from the phase three trials, first on vaccine efficacy, then on safety and reactogenicity. (cdc.gov)
  • NEW BRUNSWICK, N.J., January 29, 2021 - Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. (jnj.com)
  • The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. (jnj.com)
  • The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-19, with co-primary endpoints of 14 days and 28 days following vaccination. (jnj.com)
  • Efficacy against severe disease increased over time with no cases in vaccinated participants reported after day 49. (jnj.com)
  • After recently writing an article titled ' History of Yellow Fever in the United States ,' I spoke with Dr. Derick Kimathi , a clinical researcher at the Kenya Medical Research Institute-Wellcome Trust Research Programme (KEMRI-Wellcome Trust) who is investigating the safety and efficacy of using smaller doses of yellow fever vaccine to induce similar immunologic protection as standard doses (also known as fractional dosing). (asm.org)
  • Jessica B. Smith, M.P.H., a Kaiser Permanente researcher, and her colleagues studied whether treatment with Rituxan might reduce the efficacy of the COVID-19 vaccines. (managedhealthcareexecutive.com)
  • One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. (worldpharmanews.com)
  • COV002 is a single-blinded, multi-centre, randomised, controlled Phase II/III trial assessing the safety, efficacy and immunogenicity of AZD1222 in 12,390 participants in the UK. (worldpharmanews.com)
  • The efficacy data supporting the vaccines is neither public nor peer-reviewed, and many worry that some of them might not be as effective as their Western counterparts. (politico.eu)
  • From efficacy data to manufacturing capacity to vaccine diplomacy, POLITICO has you covered with everything you need to know about the leading Chinese vaccines. (politico.eu)
  • There's a wealth of data supporting the safety of this approach, and it's generally shown to be highly effective, although each coronavirus vaccine using this approach boasts a different efficacy rate against COVID-19. (politico.eu)
  • On November 30, 2020, Moderna announced the primary efficacy analysis of the Phase 3 study of the vaccine conducted on 196 cases. (dailyhostnews.com)
  • The primary efficacy endpoint was prevention of virologically confirmed SARS-CoV-2 infection with symptoms of COVID-19-like illness (CLI) ≥14 days after the second injection (post-dose 2 [PD2]) in participants who were SARS-CoV-2 naïve on D01 + D22. (bvsalud.org)
  • This study aimed to describe the clinical efficacy and safety of a bivalent SARS-CoV-2 recombinant protein vaccine as a two-injection primary series during a period of circulation of the omicron (B.1.1.529) variant. (bvsalud.org)
  • Overall vaccine efficacy more than 14 days after the second dose was 66·7% (95% CI 57·4-74·0), with 84 (1·0%) cases in the 8597 participants in the ChAdOx1 nCoV-19 group and 248 (2·9%) in the 8581 participants in the control group. (bris.ac.uk)
  • Exploratory analyses showed that vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 after vaccination was 76·0% (59·3-85·9). (bris.ac.uk)
  • In the present study, the adjuvanticity of a plasmid containing CpG motifs (pUC18-CpG) was introduced to enhance the efficacy of a commercial PRRS live attenuated vaccine. (visavet.es)
  • Like injected Covid vaccines, though, there are different types, and their efficacy might vary greatly. (plos.org)
  • The route can affect efficacy, too, and so could the person's current level of immunity - which previous vaccines they have had, for example. (plos.org)
  • On September 12, 2023, the CDC recommended everyone aged 6 months and older get an updated COVID-19 vaccine to protect against potentially serious outcomes of COVID-19 disease this fall and winter. (medscape.com)
  • Waning immunity from the bivalent mRNA COVID-19 vaccine or previous infection against Omicron subvariants (eg, BA.2.86, EG.5, FL.1.5.1) that emerged mid-2023 prompted development of a new formulation for 2023-2024. (medscape.com)
  • We discuss the different vectored vaccines that have been or are currently in clinical trials, with a forward-looking focus on immunogens that may be protective against seasonal and pandemic influenza infection, in the context of viral-vectored vaccines. (mdpi.com)
  • Viral cultures, molecular sampling (PCR), and serology were compared as measures of determining influenza infection. (immunizationinfo.org)
  • The various vaccine technology strategies generated non-identical immune responses to provide protection against SARS-CoV-2 infection 4 . (nature.com)
  • After three injections, the participants had chikungunya antibodies in their blood at concentrations similar to those found in people who had fought off the viral infection. (npr.org)
  • But Ledgerwood and her team won't know if that's true until they test the vaccine in more people and see how effective it is at stopping an infection. (npr.org)
  • Over the 20 weeks, 75 participants (4.5%) acquired SARS-CoV-2 infection. (cdc.gov)
  • With today's more sensitive techniques for measuring viral levels in the bloodstream, individuals who are able to maintain low levels of HIV replication can be identified soon after their infection is diagnosed. (sciencedaily.com)
  • We want to use that knowledge to develop a first-generation HIV vaccine, which may not cure or prevent infection but could successfully suppress viral levels. (sciencedaily.com)
  • In addition, ACIP discussed new age indications for Fluarix (GSK) vaccine, dose-sparing strategies for use of anthrax vaccine when vaccine demand exceeds supply, safety data for human papillomavirus (HPV) vaccine, and the epidemiology of HPV infection in males. (immunize.org)
  • Rather, all approved vaccines will be listed as viable options for the prevention of influenza infection. (immunize.org)
  • ACIP voted to include Heplisav-B (Dynavax), a recombinant hepatitis B vaccine, in the list of recommended vaccines to use against hepatitis B virus infection. (immunize.org)
  • We estimated vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for the BNT162b2, mRNA-1273, and ChAdOx1 vaccines among a population-based cohort of people with HIV in Ontario, Canada. (lww.com)
  • The four-year trial failed to stop or reduce HIV infection in some 2,500 participants. (fromthetrenchesworldreport.com)
  • Vaccines also failed to reduce infection levels in the blood. (fromthetrenchesworldreport.com)
  • "The DSMB found that the vaccine failed to reduce viral load among volunteers who acquired HIV infection at least 28 weeks after entering the study," the NIAID said in a statement released on Thursday. (fromthetrenchesworldreport.com)
  • With the BPL-1357 vaccine, especially when given intranasally, we are attempting to induce a comprehensive immune response that closely mimics immunity gained following a natural influenza infection," says Matthew Memoli, a NIAID investigator leading the vaccine trial, in a statement. (smithsonianmag.com)
  • Vaccinated people clear the infection more quickly, but the peak viral load among vaccinated people is similar to that seen in unvaccinated people, which may explain why they can still readily pass on the virus in household settings, according to a study published in The Lancet Infectious Diseases . (medicalxpress.com)
  • We found that susceptibility to infection increased already within a few months after the second vaccine dose-so those eligible for COVID-19 booster shots should get them promptly. (medicalxpress.com)
  • Demographic and vaccination status information were collected on enrolment, and participants had daily PCR tests to detect infection, regardless of whether or not they had symptroms. (medicalxpress.com)
  • By performing PCR tests on swab samples provided daily by each participant for 14-20 days, changes over time in viral load -the amount of virus in a person's nose and throat-were estimated by modeling PCR data, enabling comparisons between fully vaccinated cases of delta infection, and unvaccinated cases of delta, alpha, and pre-alpha infection. (medicalxpress.com)
  • This suggests that the risk of infection increased within three months of receiving a second vaccine dose, likely due to waning protective immunity. (medicalxpress.com)
  • The Northwestern research team has been evaluating antibody responses from the start of the pandemic and has published multiple studies following levels of antibodies from natural infection and after dose one and dose two of the vaccines. (northwestern.edu)
  • Dr Sandy Douglas, Research Group Leader and Chief Investigator of the trial, said: 'Many people are unaware that rabies still kills about 50,000 people every year, mostly in Asia and Africa - it's the only known viral infection with essentially 100% fatality. (ox.ac.uk)
  • Disruption of each of these essential cellular functions acts to suppress the interferon response to viral infection. (cdc.gov)
  • A 25-year-old man who was a resident of Washoe County in the US state of Nevada presented to health authorities on two occasions with symptoms of viral infection. (cdc.gov)
  • Hepatitis B Vaccine in Sexually Transmitted Diseases Clinics In 1990, CDC initiated a demonstration project to assess the feasibility of offering hepatitis B (HB) vaccination in sexually transmitted diseases (STD) clinics to persons at high risk for sexually transmitted HBV infection. (cdc.gov)
  • The primary analysis included all participants who were SARS-CoV-2 N protein seronegative at baseline, had had at least 14 days of follow-up after the second dose, and had no evidence of previous SARS-CoV-2 infection from NAAT swabs. (bris.ac.uk)
  • Symptoms of active viral or bacterial infection. (who.int)
  • In the current proposal, we hypothesize that reacting COVID serum from patients that have recovered from COVID infection and compare to non-infected self-serum (if available) and control healthy volunteer serum (available in our lab) may identify protein targets that have developed as a result of the COVID infection and could be useful in the development of a COVID vaccine as well as a serologic test for anti-COVID immunity. (mayo.edu)
  • Confirmed history of COVID-19 viral infection. (mayo.edu)
  • The recently identified role of SARS-CoV-2 Spike glycoprotein for inducing endothelial damage characteristic of COVID-19, even in absence of infection, is extremely relevant given that most of the authorized vaccines induce endogenous production of Spike. (researchgate.net)
  • Moreover, differences in clinical symptoms during the acute HIV-1 infection may be driven by both viral factors and innate immune responses. (lu.se)
  • The main goal of this project is to dissect the relationship between HIV-1 viral diversity, evolutionary dynamics, innate immune responses, and acute retroviral syndrome during acute HIV-1 infection, and how they contribute to disease pathogenesis during the acute and chronic stages of infection. (lu.se)
  • Clear differences in the natural history of acute HIV-1 infection exist between adults and infants both clinically and with respect to viral population dynamics and the nature of the immune response. (lu.se)
  • In this study, we plan to analyse samples that has been collected during acute HIV-1 infection (AHI) from a total of 115 participants (74 from the International AIDS Vaccine Initiative [IAVI, http://www.iavi.org/ , samples from Kenya, Uganda, Zambia, Rwanda], 26 from Sweden, and 15 from South Africa). (lu.se)
  • a single primary dose to people 18 years and older who are unable to receive or unwilling to receive other FDA-authorized or -approved COVID-19 vaccines. (medlineplus.gov)
  • a single booster dose at least 2 months after the first dose of the Janssen (Johnson and Johnson) COVID-19 vaccine for people 18 years and older who are unable to receive or unwilling to receive other FDA-authorized or -approved COVID-19 vaccines. (medlineplus.gov)
  • The Janssen (Johnson and Johnson) COVID-19 vaccine vaccination is given as a one-time dose. (medlineplus.gov)
  • a single booster dose at least two months after completion of the primary vaccination of Janssen (Johnson and Johnson) COVID-19 vaccine. (medlineplus.gov)
  • Roux, often referred to as the "disappeared" patient, volunteered for the trial (volunteer number 12312982) and received his first dose of the Pfizer vaccine on Aug. 21, 2020. (blacklistednews.com)
  • This vaccine, which is approved for use in adults ≥18 years of age, is recommended as a 2-dose schedule, with a minimum interval of 1 month between doses. (immunize.org)
  • The European Commission would have agreed to pay 15.50 euros per dose per vaccine from Pfizer and BioNTech. (abcmoney.co.uk)
  • In the trials, 12 adults received a 10-microgram dose of the BNT162b1 vaccine, 12 adults were injected with a 30-µg dose, 12 received a 100-µg dose, while nine adults were given an inert saline placebo. (nvic.org)
  • Severe pain was reported by one participant who received 100-µg dose. (nvic.org)
  • Three weeks after the initial vaccination with the Pfizer-BioNTech experimental vaccine, all clinical trial participants were given a second dose of the vaccine at the same dosage. (nvic.org)
  • After the second vaccine dose, 36 percent of trial participants between the ages of 18 and 64 reported fatigue, while 28 percent reported a headache and 18 percent reported muscle pain. (nvic.org)
  • There is no specific treatment for yellow fever, but there is a vaccine that is highly effective and offers lifelong protection after just one dose . (asm.org)
  • Interestingly, while WHO recommends a potency of 1,000 International Units (IUs) for a full dose of yellow fever vaccine, the actual potency is variable and ranges from about 13,000 to nearly 44,000 IUs per dose . (asm.org)
  • Participants included nearly 4,000 patients diagnosed with MS who received two COVID-19 mRNA vaccines or one viral vector vaccine and a booster dose. (managedhealthcareexecutive.com)
  • Over 23,000 participants are being assessed following two doses of either a half-dose/full-dose regimen or a regimen of two full doses of AZD1222 or a comparator, meningococcal conjugate vaccine called MenACWY or saline. (worldpharmanews.com)
  • Participants receive one or two intramuscular doses of a half dose (~2.5 x1010 viral particles) or full dose (~5x1010 viral particles) of AZD1222 or comparator, meningococcal vaccine MenACWY. (worldpharmanews.com)
  • In one group for the vaccine trials, participants will receive the first dose of the candidate vaccine intramuscularly and then receive a placebo nasal spray. (smithsonianmag.com)
  • In this study, participants were defined as unvaccinated if they had not received a single COVID-19 vaccine dose at least seven days before enrolment, partially vaccinated if they received one dose more than seven days before enrolment, and fully vaccinated if they received two doses more than seven days beforehand. (medicalxpress.com)
  • Of the 205 contacts, 126 (62%) received two vaccine doses , 39 (19%) had received one vaccine dose, and 40 (19%) were unvaccinated. (medicalxpress.com)
  • CanSino, meanwhile, has developed a single-dose viral vector vaccine - similar technology to the vaccines developed by Johnson & Johnson, Oxford/AstraZeneca and Sputnik - with the Chinese military. (politico.eu)
  • In a previous protocol amendment, Phase 2 study participants vaccinated with mRNA-1273 have been offered a single 50 µg booster dose of mRNA-1273. (dailyhostnews.com)
  • These are the first findings showing the antibody response to booster doses is much larger than the response after the second vaccine dose and even higher than the responses among people who had natural infections as well as full vaccination. (northwestern.edu)
  • The study also suggests protection after booster may last longer than after the second vaccine dose. (northwestern.edu)
  • Up to 192 healthy people will be randomly assigned to receive one dose of Oxford's ChAdOx2 RabG vaccine, or one or two doses of a currently licensed rabies vaccine. (ox.ac.uk)
  • The study aims to show whether a single dose of the Oxford vaccine has the potential to induce protective immune responses comparable to existing vaccines. (ox.ac.uk)
  • A single-dose, low cost vaccine would be a game changer - this trial should show us whether our new vaccine could provide that. (ox.ac.uk)
  • The vaccine has been designed to be used in a single dose regimen, with currently approved human vaccines relatively expensive and requiring repeated dosing, limiting their use where they are needed most. (ox.ac.uk)
  • Study limitations include that some healthy adult participants either did not receive dose 2 or received dose 2 outside of their protocol-defined interval and that the follow-up period was limited to 365 days for most participants. (plos.org)
  • To address the urgent medical need during the 2014 to 2016 outbreak, the clinical development of the 2-dose vaccine regimen comprising of Ad26.ZEBOV and MVA-BN-Filo was accelerated. (plos.org)
  • This Phase II study was part of this accelerated program, evaluating the safety and immunogenicity of the 2-dose vaccine regimen in healthy and HIV-infected African adults, with 28-, 56-, and 84-day intervals between doses. (plos.org)
  • Anamnestic responses were observed in all healthy participants receiving Ad26.ZEBOV as booster at 1 year after the first dose. (plos.org)
  • Volunteers must not have received any type of flu vaccination in the eight weeks prior to enrollment and must agree to forego seasonal flu vaccination for approximately two months after the second vaccine (or placebo) dose. (nih.gov)
  • Interpretation: In the context of changing circulating viral variants, it is challenging to induce protection in naïve individuals with a two-dose priming schedule based on the parental D614 strain. (bvsalud.org)
  • In the UK trial, a subset of participants received a lower dose (2·2 × 1010 viral particles) of the ChAdOx1 nCoV-19 for the first dose. (bris.ac.uk)
  • Safety was assessed in all participants who received at least one dose. (bris.ac.uk)
  • The results of this primary analysis of two doses of ChAdOx1 nCoV-19 were consistent with those seen in the interim analysis of the trials and confirm that the vaccine is efficacious, with results varying by dose interval in exploratory analyses. (bris.ac.uk)
  • Abstract Cohorts of healthy younger adults (18-50yrs) and healthy older adults (60-75yrs) were immunized intramuscularly or intranasally with an adenovirus-vectored RSV vaccine (PanAd3-RSV) as a prime dose and boosted with PanAd3-RSV or a poxvirus-vectored vaccine (MVA-RSV) encoding the same insert. (ox.ac.uk)
  • These vaccines would not be expected to protect against very different influenza strains, such as might be seen during a pandemic. (immunizationinfo.org)
  • Timely evaluation of the protective effects of Coronavirus Disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern is urgently needed to inform pandemic control planning. (nature.com)
  • Most participants agreed in principle that better access to human influenza vaccines, in particular those against H5N1 and pandemic disease, is one of the most important benefits. (who.int)
  • In a pandemic setting, vaccine matching and development could take up to six months, during which time the population is vulnerable. (scienceboard.net)
  • An influenza virus vaccine that results in broad immunity would likely protect against any emerging influenza virus subtype or strain and would significantly enhance our pandemic preparedness, avoiding future problems with influenza pandemics as we see them now with COVID-19," said author Florian Krammer, PhD, professor of microbiology at the Icahn School of Medicine at Mount Sinai, in a statement. (scienceboard.net)
  • Johnson & Johnson embarked on the global effort to combat the COVID-19 pandemic a year ago, and has brought the full force of our capabilities, as well as tremendous public-private partnerships, to enable the development of a single-shot vaccine. (jnj.com)
  • A one-shot vaccine is considered by the World Health Organization to be the best option in pandemic settings, enhancing access, distribution and compliance. (jnj.com)
  • AstraZeneca continues to engage with governments, multilateral organisations and collaborators around the world to ensure broad and equitable access to the vaccine at no profit for the duration of the pandemic. (worldpharmanews.com)
  • Before the pandemic, it would take 10-15 years to develop a vaccine from inception to licencing, yet the COVID-19 vaccines data was collected over two months. (bmj.com)
  • Influenza vaccines that can provide long-lasting protection against a wide range of seasonal influenza viruses, as well as those with pandemic potential, would be invaluable public health tools," says NIAID director Anthony S. Fauci in a statement. (smithsonianmag.com)
  • Professor Ajit Lalvani of Imperial College London, UK, who co-led the study, said that "vaccines are critical to controlling the pandemic, as we know they are very effective at preventing serious illness and death from COVID-19. (medicalxpress.com)
  • China has been one of the leaders in developing coronavirus vaccines throughout the pandemic, having now approved for use four homegrown vaccines. (politico.eu)
  • China has led in vaccine development throughout the pandemic. (politico.eu)
  • Current ongoing research in our laboratory is mainly focused on developing assays to assess the potency of seasonal and pre-pandemic influenza vaccines, and to evaluate humoral immune responses elicited by vaccines against viral diseases, including SARS CoV-2 as well as Influenza A H5N1 and H7N9. (joinhandshake.com)
  • Influenza vaccines that can provide long-lasting protection against a wide range of seasonal influenza viruses as well as those with pandemic potential would be invaluable public health tools," said NIAID Director Anthony S. Fauci, M.D. "The scientific community is making progress on this pressing global health priority. (nih.gov)
  • Any decision about whether to continue the trial is complex because it's difficult to assess the cause of a rare injury that occurs during a vaccine trial - and because scientists and authorities have to weigh the risk of uncommon side effects against a vaccine that might curb the pandemic. (thestkittsnevisobserver.com)
  • Alongside traditional public health measures how quickly we can collectively expand vaccine manufacturing and roll out vaccines to all countries will determine how soon we can control this pandemic. (bvsalud.org)
  • mRNA-1273.211 is a multivalent candidate which combines mRNA-1273, Moderna's authorized vaccine against ancestral strains, and mRNA-1273.351 in a single vaccine, designed to elicit a broad immune response as both a primary series and when administered as a boost to those who have previously received mRNA-1273. (dailyhostnews.com)
  • In parallel, NIAID, part of the National Institutes of Health (NIH), will conduct a Phase 1 clinical trial to assess the monovalent and multivalent modified mRNA-1273 vaccines as a primary series in naïve individuals and as a booster vaccine in those previously vaccine with mRNA-1273. (dailyhostnews.com)
  • Two of those people had received the vaccine and four had received a placebo. (politifact.com)
  • Within seven days of vaccination, seven (58.3 percent) of the participants in the 10-µg group reported adverse reactions (pain) near the injection site and 24-or 100 percent-in the 30-µg and 100-µg groups and two (22.2 percent) in the placebo group reported reactions. (nvic.org)
  • 29 were in the placebo group and two in the vaccine group. (cdc.gov)
  • Serious adverse events were reported in a similar proportion among recipients of vaccine and placebo. (cdc.gov)
  • The researchers conducted a randomized, multicenter, observer-blind, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of the group 1 cHA-based vaccine (a live attenuated or inactive influenza virus vaccine expressing a cH8/1 HA and an N1 NA with a backbone from a master donor stain) in 65 participants in the U.S. (scienceboard.net)
  • The HVTN 505 vaccine was given to 1,250 participants, with 1,244 receiving a placebo. (fromthetrenchesworldreport.com)
  • Forty-one infections were detected among those who had received the real vaccine, versus 30 in the placebo group. (fromthetrenchesworldreport.com)
  • Additionally, an increase in HIV acquisition was noted among volunteers in the 'investigational' vaccine group, as opposed to the placebo group. (fromthetrenchesworldreport.com)
  • Another group of participants will receive a placebo shot and the actual vaccine as a nasal spray. (smithsonianmag.com)
  • The placebo-controlled trial will test the safety of a candidate vaccine, BPL-1357, and its ability to prompt immune responses. (nih.gov)
  • In the Phase 1 trial, volunteers will be randomized in a 1:1:1 ratio into three groups and will receive two doses of placebo or vaccine spaced 28 days apart. (nih.gov)
  • In addition to the two clinic visits to receive vaccine (or placebo), volunteers will be asked to return to the clinic seven times to provide blood and nasal mucosal samples that will be used by the investigators to detect and characterize immune responses. (nih.gov)
  • Participants were randomized 1:1 to receive two intramuscular injections of a monovalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant (10 µg of the spike (S) protein from the ancestral D614 strain) or placebo on Day 1 (D01) and Day 22 (D22). (bvsalud.org)
  • As previously described, individuals 18 years and older were randomly assigned 1:1 to receive two standard doses of ChAdOx1 nCoV-19 (5 × 1010 viral particles) or a control vaccine or saline placebo. (bris.ac.uk)
  • The vaccine was safe and produced some degree of immunity in a preliminary study. (npr.org)
  • This genetic change, or shift, in the virus results in immunity to only specific strains of the influenza virus, requiring frequent re-formulation and re-administration of seasonal vaccines. (scienceboard.net)
  • A single rubella vaccination, usually given as measles-mumps-rubella (MMR) vaccine, is thought to confer lifelong immunity. (cdc.gov)
  • Therefore, serologic testing of NHANES participants will be conducted to document the level of immunity to rubella by race and ethnicity and allow comparison data from NHANES III. (cdc.gov)
  • NHANES provides a unique opportunity to assess changes in the seroprevalence of immunity to varicella after introduction of the vaccine. (cdc.gov)
  • This is very different than nearly all other vaccines for influenza or other respiratory viruses, which focus on inducing immunity to a single viral antigen and often do not induce mucosal immunity. (smithsonianmag.com)
  • The race for a vaccine that might be able to provide at least some "sterilizing" immunity just got a boost in the US: A new $5 billion program from the White House called "Project Next Gen" is partly dedicated to speeding up mucosal vaccines. (plos.org)
  • Since the start of the COVID-19 outbreak, the race for testing new platforms designed to confer immunity against SARS-CoV-2, has been rampant and unprecedented, leading to conditional emergency authorization of various vaccines. (researchgate.net)
  • The Janssen (Johnson and Johnson) coronavirus disease 2019 (COVID-19) vaccine is currently being studied to prevent coronavirus disease 2019 caused by the SARS-CoV-2 virus. (medlineplus.gov)
  • MedImmune/AstraZeneca) as an option in the list of recommended influenza vaccines for the 2018-2019 influenza season. (immunize.org)
  • However, vaccine availability may be limited during the 2018-2019 season because many providers, including state health department VFC programs, have already completed vaccine orders for the upcoming season. (immunize.org)
  • Coronavirus disease 2019 vaccine effectiveness among a popul. (lww.com)
  • People with HIV were underrepresented in coronavirus disease 2019 (COVID-19) vaccine clinical trials. (lww.com)
  • Mandatory vaccination was proposed as a solution to childhood vaccine hesitancy in 2019 by Health Secretary Matt Hancock. (bmj.com)
  • The first participant was enrolled on 9 November 2015, and the date of last participant's last visit was 12 February 2019. (plos.org)
  • Most current influenza vaccines target the immunodominant head domain of the viral HA and therefore antibodies produced by these vaccines are strain specific. (scienceboard.net)
  • Scientists believe that vaccines using a version of the whole coronavirus may generate a broader immune response, including producing antibodies in the mucosal membrane in the nose and throat. (politico.eu)
  • With the weak vaccine-elicited by neutralizing antibodies against the SARS-CoV-2 Delta variant, there is an impending fear of severe breakthrough infections. (news-medical.net)
  • The two that the US has put its biggest bets on are the mRNA vaccines from Moderna and Pfizer. (medscape.com)
  • Pfizer and BioNTech, Moderna, AstraZeneca and Oxford … The most advanced vaccines against Covid 19 are being prepared to request authorization through the emergency route for their distribution and will begin to be supplied throughout December and early 2021. (abcmoney.co.uk)
  • Moderna plans to request authorization from the US for the distribution of its vaccine during these weeks. (abcmoney.co.uk)
  • As the media rush to hail the new vaccine - bolstered by the subsequent news Moderna have a 95% effective vaccine in trials - it is important to ensure that information communicated to the public be truthful, transparent and accurate. (bmj.com)
  • CAMBRIDGE, Mass.-(BUSINESS WIRE)- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participants have been dosed with the Company's modified COVID-19 vaccines, designed to address the potential need for booster vaccine candidates, in an amendment to the ongoing Phase 2 clinical study. (dailyhostnews.com)
  • Previously published data has shown that vaccination with the Moderna COVID-19 Vaccine produced neutralizing titers against all key variants tested, including B.1.1.7, first identified in the UK, and B.1.351, with a 6-fold reduction in neutralizing titers against B.1.351. (dailyhostnews.com)
  • The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from the National Institute of Allergy and Infectious Disease's (NIAID) Vaccine Research Center. (dailyhostnews.com)
  • The first participant in the NIAID-led Phase 1 study of the Moderna COVID-19 Vaccine was dosed on March 16, 2020, 63 days from sequence selection to Phase 1 study dosing. (dailyhostnews.com)
  • On May 12, 2020, the U.S. Food and Drug Administration granted the Moderna COVID-19 Vaccine Fast Track designation. (dailyhostnews.com)
  • Results from the second interim analysis of the NIH-led Phase 1 study of the Moderna COVID-19 Vaccine in the 56-70 and 71+ age groups were published on September 29, 2020 in The New England Journal of Medicine. (dailyhostnews.com)
  • Nine months after individuals had two doses of the Pfizer or Moderna vaccines, their neutralizing antibody levels to SARS-CoV-2 decreased about 10-fold. (northwestern.edu)
  • Information from clinical trials is available at this time to support the use of Janssen (Johnson and Johnson) COVID-19 vaccine to prevent COVID-19. (medlineplus.gov)
  • In clinical trials, approximately 21,895 individuals 18 years of age and older have received the Janssen (Johnson and Johnson) COVID-19 vaccine. (medlineplus.gov)
  • The document details safety data collected during Pfizer's vaccine trials, including "serious adverse events," which the FDA defines as "any undesirable experience associated with the use of a medical product in a patient. (politifact.com)
  • An 80,000-page cache of Pfizer-BioNTech COVID-19 vaccine documents released by the U.S. Food and Drug Administration sheds light on Pfizer's extensive vaccine trials in Argentina, including the unusually large size of the trials and the story of a trial participant whose vaccine reaction was deleted. (blacklistednews.com)
  • An 80,000-page cache of Pfizer-BioNTech COVID-19 vaccine documents released by the U.S. Food and Drug Administration (FDA) sheds light on Pfizer's extensive vaccine trials in Argentina , including the unusually large size of the trials and the story of a trial participant whose vaccine reaction was "disappeared. (blacklistednews.com)
  • Vaccine trials in Argentina also appear to have glossed over adverse events suffered by other trial participants, and the potential connection between the adverse events and the vaccine. (blacklistednews.com)
  • As previously reported by The Defender , the documents included Case Report Forms from Pfizer COVID vaccine trials in the U.S., and the " third interim report " from BioNTech's trials conducted in Germany, both of which listed adverse events sustained by participants in the U.S. and German trials. (blacklistednews.com)
  • Several bloggers and online investigators called into question various aspects of the Argentine vaccine trials, pointing out the number of participants in the Argentine trials dwarfed that of other, typically smaller trials at other locations in different countries. (blacklistednews.com)
  • In all, 4,501 patients participated in the Argentine trials, representing 10% of all Pfizer trial participants worldwide. (blacklistednews.com)
  • But obviously there are several other vaccines, eight that are in phase 3 trials. (medscape.com)
  • We don't know if the vaccines are going to work, and how well, and what the side effects will be, but we will get some information as we get into the New Year," said Dr. William Schaffner, an infectious-disease specialist at Vanderbilt Medical Center in Nashville, Tennessee, who is not involved with the trials. (livescience.com)
  • More than 50 percent of adult participants involved in the Phase 1/2 human trials of Pfizer and BioNTech's experimental messenger RNA (ribonucleic acid) COVID-19 vaccine reported adverse reactions. (nvic.org)
  • Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. (worldpharmanews.com)
  • The global trials are evaluating participants aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions. (worldpharmanews.com)
  • US authorities have announced the cessation of clinical trials in the US after a vaccine designed to prevent the spread of HIV was revealed to be ineffective. (fromthetrenchesworldreport.com)
  • The National Institutes of Health (NIH) announced on Tuesday that a universal flu vaccine has moved to phase I clinical trials, where scientists will test for human safety and appropriate dosage sizes. (smithsonianmag.com)
  • The phase I trials allow researchers to see if the vaccine can induce a wide and durable response against the flu virus in people, per Gizmodo , as opposed to the often incomplete protection offered by traditional vaccines that need to be received every year . (smithsonianmag.com)
  • Human papillomavirus (HPV) vaccines are a powerful public licensure clinical trials. (cdc.gov)
  • Although vaccine safety is rigorously assessed during for females age 9-26 years in 2006, and for males in the same pre-licensure clinical trials, sample sizes are not adequate to age group in 2009. (cdc.gov)
  • Internationally, a handful of mucosal vaccines are already in use, more than a dozen others are in clinical trials, and results of preclinical studies have been released for well over a hundred more, including several developed with or by the US NIH. (plos.org)
  • 4 more vaccines have entered clinical trials, bringing the total to 24. (plos.org)
  • Most of the vaccines in clinical trials are viral vector vaccines. (plos.org)
  • No additional vaccine has advanced into phase 3 trials. (plos.org)
  • Immune response was inadequate, and that vaccine hasn't progressed to further trials. (plos.org)
  • Two other coronavirus vaccines are also in late-stage trials in the U.S. (thestkittsnevisobserver.com)
  • The lack of thorough testing in animals prior to clinical trials, and authorization based on safety data generated during trials that lasted less than 3.5 months, raise questions regarding vaccine safety. (researchgate.net)
  • Given the high rate of occurrence of adverse effects that have been reported to date, as well as the potential for vaccine-driven disease enhancement, Th2-immunopathology, autoimmunity, and immune evasion, there is a need for a better understanding of the benefits and risks of mass vaccination, particularly in groups excluded from clinical trials. (researchgate.net)
  • was funded through an existing CDC cooperative agreement and conducted in over 1600 HCP working in 20 U.S. centers over 20 weeks from May to December 2020, before the availability of COVID-19 vaccines. (cdc.gov)
  • On December 11, 2020, the FDA issued an Emergency Use Authorization (EUA) for Pfizer-BioNTech's messenger RNA (mRNA) COVID-19 vaccine for use in persons 16 years of age and older. (nvic.org)
  • December 7, 2020 -- A new universal influenza vaccine has been developed that targets the stalk portion of the influenza virus surface protein rather than the head portion. (scienceboard.net)
  • The new study enrolled 621 participants, identified by the UK contact tracing system, between September 2020 and September 2021. (medicalxpress.com)
  • On May 29, 2020, the first participants in each age cohort: adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300) were dosed in the Phase 2 study of the vaccine. (dailyhostnews.com)
  • On July 28, 2020, results from a non-human primate preclinical viral challenge study evaluating the vaccine were published in The New England Journal of Medicine. (dailyhostnews.com)
  • On July 14, 2020, an interim analysis of the original cohorts in the NIH-led Phase 1 study of the vaccine was published in The New England Journal of Medicine. (dailyhostnews.com)
  • Between April 23 and Dec 6, 2020, 24 422 participants were recruited and vaccinated across the four studies, of whom 17 178 were included in the primary analysis (8597 receiving ChAdOx1 nCoV-19 and 8581 receiving control vaccine). (bris.ac.uk)
  • Arthur Allen and Liz Szabo, Kaiser Health News- September 14, 2020- The Food and Drug Administration in the US is weighing whether to follow British regulators in resuming a coronavirus vaccine trial that was halted when a participant suffered spinal cord damage, even as the National Institutes of Health has launched an investigation of the case. (thestkittsnevisobserver.com)
  • A recent blog post about the deaths of people who volunteered for Pfizer's COVID-19 vaccine trial sounds scary but it's misleading, and lacking context. (politifact.com)
  • The Food and Drug Administration recently released a briefing document for the Dec. 10 meeting of its vaccine advisory panel, which recommended that the FDA give Pfizer's COVID-19 vaccine emergency use authorization. (politifact.com)
  • Among 43,448 people enrolled in Pfizer's vaccine trial, six people died. (politifact.com)
  • The FDA on May 2 released the latest cache of documents, which pertain to the Emergency Use Authorization of Pfizer's vaccine, as part of a court-ordered disclosure schedule stemming from an expedited Freedom of Information Act request filed in August 2021. (blacklistednews.com)
  • The price is cheaper than that of Pfizer's vaccine but more expensive than Oxford's: it will be below 21 euros, but it has not been specified. (abcmoney.co.uk)
  • If approved, Pfizer's jab will be the first in a new era of vaccines. (bmj.com)
  • Instead of using a traditional approach, such as an attenuated, or weakened, viral vector , Pfizer's vaccine uses viral mRNA as "molecular instructions for human cells to make the coronavirus spike protein" . (bmj.com)
  • If you have a history of blood clots with low platelets following the Janssen (Johnson and Johnson) COVID-19 vaccine or AstraZeneca (not currently approved in the US) COVID-19 vaccines, you should not receive the Janssen (Johnson and Johnson) COVID-19 vaccine. (medlineplus.gov)
  • AstraZeneca and Oxford have announced that the study carried out in the United Kingdom and Brazil on their vaccine showed that it was very effective in preventing Covid 19, and no hospitalizations or serious cases of the disease were reported in the participants who received the vaccine. (abcmoney.co.uk)
  • This is a weakened version of a common cold virus (adenovirus) that has been genetically modified so that it is impossible for it to replicate in humans, and is similar to the technology used successfully in the Oxford-AstraZeneca COVID-19 vaccine. (ox.ac.uk)
  • For the AstraZeneca viral vector vaccine in intranasal form. (plos.org)
  • Astrazeneca Oxford Vaccine-Stop, Go, Stop. (thestkittsnevisobserver.com)
  • AstraZeneca, which is running the global trial of the vaccine it produced with Oxford University, said the trial volunteer recovered from a severe inflammation of the spinal cord and is no longer hospitalized. (thestkittsnevisobserver.com)
  • AstraZeneca "need[s] to be more forthcoming with a potential complication of a vaccine which will eventually be given to millions of people," said Nath. (thestkittsnevisobserver.com)
  • Millions of people have received the vaccine under EUA since February 27, 2021. (medlineplus.gov)
  • The Company is making rapid progress in manufacturing with a capacity of up to 3 billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval. (worldpharmanews.com)
  • Findings: Between May 26 and November 7, 2021, 10,114 participants received ≥1 study injection, and 9441 participants received both injections. (bvsalud.org)
  • To redirect immune responses from the head to the stalk, researchers from Mount Sinai have developed a sequential chimeric HA (cHA) vaccine. (scienceboard.net)
  • Studies have found that humoral-mediated (B-cell mediated) immune responses to COVID-19 vaccines are dampened in MS patients who receive B-cell-depleting treatments, such as Rituxan. (managedhealthcareexecutive.com)
  • This study will generate important data on safety and ability of the candidate vaccine to induce effective immune responses and their duration in an endemic population. (ox.ac.uk)
  • CIGB (Cuba), the manufacturers of Mambisa, an intranasal protein subunit vaccine, have reported to a conference that immune responses have been high in their trial. (plos.org)
  • Previous studies by us and others have suggested that differences in disease progression rate may be associated with both viral parameters, such as diversity or infecting subtype and host immune responses. (lu.se)
  • In June 2023, VRBPAC recommended the vaccine composition be updated to a 2023-2024 formulation to target the XBB.1.5 Omicron subvariant. (medscape.com)
  • Both revised mRNA vaccine with the XBB.1.5 composition (ie, Spikevax and Comirnaty ) received supplemental approval for adolescents and adults in September 2023. (medscape.com)
  • The following tables summarize the 2023-2024 COVID-19 vaccine schedule, including those who are immunocompromised. (medscape.com)
  • COVID-19 Vaccine, Viral Vector (Johnson and Johnson/Janssen) is no longer commercially available in the U.S and the Emergency Use Authorization has been revoked as of 6/1/2023. (medlineplus.gov)
  • 1 more vaccine has been authorized in China - Pneucolin, a viral vector nasal spray from Beijing Wantai BioPharm. (plos.org)
  • an inhaled viral vector vaccine from Wuhan BravoVax (China). (plos.org)
  • 1 more vaccine has progressed to phase 2 trial - an intranasal viral vector vaccine from CyanVac (US). (plos.org)
  • How efficacious are the injectable trivalent inactivated (TIV) and the intranasal attenuated (LAIV) influenza vaccines in healthy adults? (immunizationinfo.org)
  • Both TIV and LAIV influenza vaccines were efficacious at preventing laboratory-confirmed influenza in healthy adults, although LAIV was less so. (immunizationinfo.org)
  • Those eligible to participate in the Elite Controller Collaborative Study are HIV-positive adults, aged 18 to 75, who have maintained viral loads below 2,000 copies without taking HIV antiviral medications. (sciencedaily.com)
  • Pfizer) vaccination among adults ≥65, vaccines for the prevention and treatment of healthcare-associated infections, the epidemiology of meningococcal disease among college students, and activities being conducted by the Japanese encephalitis vaccine workgroup. (immunize.org)
  • Recently-approved RSV vaccines are now available for older adults and pregnant mothers . (cbsnews.com)
  • The vaccine candidate was 85 percent effective in preventing severe disease across all regions studied, [i] 28 days after vaccination in all adults 18 years and older. (jnj.com)
  • We conducted a randomised trial to assess the safety and the immunogenicity of the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in 3 different vaccination intervals in healthy and HIV-infected adults. (plos.org)
  • A portion of the hepatitis B virus gene, coding for HBsAg, is cloned into yeast, and the vaccine for hepatitis B is produced from cultures of this recombinant yeast strain according to methods developed in the Merck Research Laboratories. (theodora.com)
  • This shortened and simplified dosage schedule is anticipated to improve hepatitis B vaccine coverage. (immunize.org)
  • The company's studies evaluating the shedding and antibody responses of the H1N1 strain in children 2-4 years of age demonstrated the vaccine performed significantly better following inclusion of a new H1N1 component strain (A/Slovenia). (immunize.org)
  • Study participants developed increased antibody levels and exhibited increased viral shedding, an indicator of improved vaccine virus replication. (immunize.org)
  • The team found that a single vaccination with adjuvanted, inactivated cHA vaccines induced remarkably high anti-stalk antibody titers. (scienceboard.net)
  • Because these antibody levels are so robust, the booster could potentially give us protection for a longer duration than what we saw for two doses of the vaccine," said co-corresponding author Alexis Demonbreun, an assistant professor of pharmacology at Northwestern University Feinberg School of Medicine. (northwestern.edu)
  • Our group has explored the use of genomic RNA/phage display libraries derived from primary human malignant melanoma cells as a means of identifying antibody detectable targets on cancer cells (cancer vaccines or antibody guided therapeutics). (mayo.edu)
  • Most of the strains of influenza A (H3N2) and B viruses circulating during the winter of 2004-2005 were not the same as the strains in that season's vaccines. (immunizationinfo.org)
  • It is reassuring, but also surprising, that these influenza vaccines were as efficacious as was observed given the differences between the strains causing illness and those in the vaccines. (immunizationinfo.org)
  • This vaccine, which is capable of neutralizing diverse strains of influenza, was evaluated in a phase I clinical study whose results were published in Nature Medicine on December 7. (scienceboard.net)
  • When developing influenza vaccines, researchers are forced to predict the genetic makeup of the virus some months in advance, and mismatches occur relatively frequently as strains become antigenically diverse. (scienceboard.net)
  • This makes it more difficult to match strains to vaccines. (scienceboard.net)
  • Our chimeric HA vaccine, by contrast, is directed at the proximal part of the HA protein -- the stalk domain -- which has been shown to broadly neutralize diverse influenza virus strains in both animal models and humans. (scienceboard.net)
  • Our chimeric hemagglutinin vaccine is a major advance over conventional vaccines which are often mismatched to the circulating strains of virus, impacting their effectiveness. (scienceboard.net)
  • The vaccine, known as BPL-1357, was developed by experts at the National Institute of Allergy and Infectious Diseases (NIAID) and contains four strains of non-infectious, chemically inactivated avian influenza, thought to be not highly pathogenic. (smithsonianmag.com)
  • Researchers found that the shot protected small mammals from lethal doses of six different flu strains, showing the promise of a universal vaccine against the flu. (smithsonianmag.com)
  • BPL-1357 is a whole-virus vaccine made up of four strains of non-infectious, chemically inactivated, low-pathogenicity avian flu virus. (nih.gov)
  • A study in animals , led by NIAID investigator Jeffery K. Taubenberger, M.D., Ph.D., and posted online as a pre-print, found that all mice receiving two doses of BPL-1357 vaccine delivered either intramuscularly or intranasally survived later exposure to lethal doses of each of six different influenza virus strains, including subtypes that were not included in the vaccine. (nih.gov)
  • New vaccines developed against variant strains may provide cross-protection against emerging variants when used as boosters and facilitate vaccination across a range of countries, healthcare settings and populations. (bvsalud.org)
  • Both killed and live attenuated vaccines are currently used against the disease, but neither of them could provide full protection after vaccination. (visavet.es)
  • The sixth mucosal vaccine in phase 3 is a live attenuated nasal spray from Codagenix (US), being manufactured by the Serum Institute of India. (plos.org)
  • Scientists are moving closer to creating a universal flu vaccine. (smithsonianmag.com)
  • Volunteer in trial of candidate universal flu vaccine BPL-1357 receives an intramuscular injection. (nih.gov)
  • United States (US): bivalent HPV vaccine (CervarixÒ [2vHPV] tional post-licensure safety data have accumulated. (cdc.gov)
  • The FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) continues to assess the optimal composition of COVID-19 primary and booster vaccines. (medscape.com)
  • These DNA-based vaccines, designed to alert the immune system, were then followed up with a single 'booster' injection in the 24th week. (fromthetrenchesworldreport.com)
  • The authors point to vaccine waning as important evidence for all eligible people to receive booster shots. (medicalxpress.com)
  • mRNA-1273.351 encodes for the prefusion stabilized Spike protein of the SARS-CoV-2 variant B.1.351, first identified in the Republic of South Africa, and is being assessed as a booster vaccine to increase the breadth of response to emerging variants with key-receptor-binding domains (RBD) mutations. (dailyhostnews.com)
  • Finger-stick dried blood spot samples were self-collected prior to booster administration and six to 10 days after receiving a mRNA booster vaccine. (northwestern.edu)
  • In Malaysia, three doses of trivalent oral polio vaccine are administered at 2, 3 and 5 months of age, followed by booster doses at 18 months and 6 years. (who.int)
  • The vaccines were also granted Emergency Use Authorization (EUA) for children aged 6 months through 11 years. (medscape.com)
  • In other words, none of the deaths were attributed to the vaccine , and the briefing document endorsed its emergency-use authorization, saying it had a "favorable safety profile, with no specific safety concerns. (politifact.com)
  • Researchers working on a vaccine against the Zaire strain of Ebola virus, which is causing the current outbreak, say that nearly 200 people have now received an experimental vaccine that was developed by the U.S. National Institutes of Health (NIH) and GlaxoSmithKline. (livescience.com)
  • The study was small: Only 25 people were given the experimental vaccine. (npr.org)
  • Overall, the experimental vaccine was well tolerated by the volunteers. (npr.org)
  • This experimental vaccine isn't the first for chikungunya. (npr.org)
  • Professor Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial at Oxford, said: "These findings show that we have an effective vaccine that will save many lives. (worldpharmanews.com)
  • The highly communicable nature of poliovirus and existence of an effective vaccine led to the launch of the Global Polio Eradication Initiative by the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention, and the United Nations Children's Fund in 1988. (who.int)
  • It's already clear, though, that there's going to be a wide range of results from vaccine to vaccine, just as there was with injected Covid vaccines. (plos.org)
  • There are now more than 150 published reports of preclinical studies of mucosal Covid vaccines. (plos.org)
  • To start filling in that second gap, a team of researchers at the National Institutes of Allergy and Infectious Diseases in Bethesda designed a vaccine using virus-like particles , a new technology. (npr.org)
  • Back in the 1980s, a team at the U.S. Army Medical Research Institute of Infectious Diseases created a vaccine with a live, weakened version of the virus. (npr.org)
  • Trial participants to date are aged 18 years or over, who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus. (worldpharmanews.com)
  • The vaccine candidate was developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID). (nih.gov)
  • Moderna's vaccine is also one of the candidates based on RNA technology. (abcmoney.co.uk)
  • Moderna's vaccine is kept at a temperature of 20º below zero , compared to the 70º below zero required by Pfizer and BioNTech, which is an advantage for its maintenance. (abcmoney.co.uk)
  • There have been preclinical studies released at least on most vaccine types, including Moderna's mRNA vaccine. (plos.org)
  • persons aged 12 years are eligible to receive attendance at large public gatherings that include travelers the Pfizer-BioNTech COVID-19 vaccine. (cdc.gov)
  • A Strategy for Accelerating the Development of Preventive AIDS Vaccines Could a screening test of concept trial, with an endpoint of plasma HIV-RNA VL at setpoint in infected participants, reduce to 30 the number of needed infections to achieve adequate statistical power? (medscape.com)
  • Exactly 2,504 volunteers across 19 US cities - all gay men or transgendered people who had sex with men - participated in the massive federally backed study, which hoped to determine whether a vaccine program could prevent HIV infections or reduce the 'viral load': The amount of virus in the blood of infected patients. (fromthetrenchesworldreport.com)
  • We are committed to advancing medical research understanding of how common viral infections affect the human body, to develop future treatments in a quick and effective way. (50connect.co.uk)
  • Hib disease occurred primarily in children under 5 years of age, and in the United States prior to the initiation of a vaccine program was estimated to account for nearly 20,000 cases of invasive infections annually, approximately 12,000 of which were meningitis. (theodora.com)
  • This new regional action framework was developed with the aim of achieving an African Region where the public health threats of HIV, tuberculosis, viral hepatitis and sexually transmitted infections are controlled or eliminated. (who.int)
  • According to the briefing document, both vaccine recipients who died were older than 55. (politifact.com)
  • Serology studies showed that neutralizing activity against the Omicron variant decreased substantially in recipients of two COVID-19 vaccine doses 9 , 10 . (nature.com)
  • 7%, of vaccine recipients seroconverted compared to 37 or 2. (cdc.gov)
  • Interim analyses of the COVID-19 mRNA vaccines have demonstrated the XBB.1.5-containing monovalent vaccines elicit potent neutralizing responses against variants of the omicron XBB-lineage (XBB.1.5, XBB.1.6, XBB.2.3.2, EG.5.1, and FL.1.5.1) as well as the recently emerged BA.2.86 variant. (medscape.com)
  • Of particular concern is the elderly population known to elicit weaker immunological responses to vaccines. (bmj.com)
  • The companies have applied to health regulators in the US for authorization for the emergency use of their vaccine and are expected to receive light. (abcmoney.co.uk)
  • A lot of the language that surrounds this - "warp speed," "finalist," "race for a vaccine" - scares people that either timelines are being inappropriately truncated or, worse, that safety guidelines are being ignored. (medscape.com)
  • An independent Data Safety Monitoring Board determined that the analysis met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine. (worldpharmanews.com)
  • Prior to the introduction of the vaccine, it was estimated that 17% of all cases of Hib disease occurred in infants less than 6 months of age. (theodora.com)
  • The vaccine was found to be safe and immunogenic in a phase I clinical trial. (mdpi.com)
  • So far, data is showing promising results, indicating that the vaccine will likely move into a Phase II trial, they said, which would continue to evaluate the vaccine's safety as well as look at its effectiveness. (livescience.com)
  • That vaccine completed a phase 2 clinical trial . (npr.org)
  • This was spread over 10 follow-up visits to mimic phase a 2b HIV vaccine clinical trial follow up and duration. (scirp.org)
  • Data from a subset of 8,000 participants aged 18 years or older in the phase 2/3 study demonstrates that "the vaccine was well tolerated" and that most adverse effects "resolved shortly after vaccination. (abcmoney.co.uk)
  • Although the definitive data of this vaccine are not yet known, the side effects reported in an earlier phase of the study of this vaccine were similar to those of the previous ones. (abcmoney.co.uk)
  • The University of Oxford and the Ifakara Health Institute today announced the vaccination of the first participants in a Phase Ib/II trial testing a novel rabies vaccine in human volunteers in Tanzania. (ox.ac.uk)
  • A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland. (nih.gov)
  • An oral vaccine in phase 2 has reportedly been put on hold, as its manufacturer, Vaxart (US), switches to developing an oral pancoronavirus vaccine. (plos.org)
  • Vaccines are important preventive measures against severe COVID-19 disease, hospitalization, death, and persistent symptoms (ie, long COVID). (medscape.com)
  • Participants with CRAB criteria that are attributable to conditions other than the disease under study may be eligible after discussion with the Sponsor Investigator. (dana-farber.org)
  • The Centers for Disease Control and Prevention says it has launched a new public relations campaign this year to "reset expectations" around the influenza vaccine, after the agency's consumer research found some Americans misunderstand the benefits of the annual shot. (cbsnews.com)
  • The term 'viral respiratory disease season' seemed long and unnecessary and an escalation that felt scary to many. (cbsnews.com)
  • The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunization, is a critical component of the global public health response," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. (jnj.com)
  • Wide use of the vaccine may change the epidemiology of the disease with a shift in incidence to older persons who are at higher risk than are younger persons for more severe disease and complications. (cdc.gov)
  • The staff of the Immunoserology Unit of the California State Department of Health Services (CSDHS), Viral and Rickettsial Disease Laboratory (VRDL) developed these EIA tests. (cdc.gov)
  • Vaccines remain highly effective at preventing severe disease and deaths from COVID-19, but some studies suggest they may be less effective against the delta variant -currently the dominant strain worldwide-though the reason for this has not been established. (medicalxpress.com)
  • Importantly, according to the United States Centers for Disease Control and Prevention (CDC), people who have not been vaccinated are 11 times more likely to get infected with COVID-19, thus indicating the important role of vaccines and the protection it renders from the Delta variant. (news-medical.net)
  • Prior to the introduction of Haemophilus b conjugate vaccines, Haemophilus influenzae type b (Hib) was the most frequent cause of bacterial meningitis and a leading cause of serious, systemic bacterial disease in young children worldwide. (theodora.com)
  • Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. (mayo.edu)
  • Poliomyelitis is a contagious viral disease, which mainly affects children below five years of age. (who.int)
  • We applied the VE-GD model to predict protection mediated by existing vaccines against new genetic variants and validated the results by published real-world and clinical trial data, finding high concordance of predicted VE with observed VE. (nature.com)
  • The VE-GD framework enables predictions of vaccine protection in real time and offers a rapid evaluation method against novel variants that may inform vaccine deployment and public health responses. (nature.com)
  • However, the protective effect of the various vaccine products is challenged by new genetic variants. (nature.com)
  • Among all the influencing factors, emerging genetic variants relative to the vaccine strain play a critical role in determining vaccine effectiveness. (nature.com)
  • Background: The literature on first generation COVID-19 vaccines show they were less effective against new SARS-CoV-2 variants of concern including Omicron (BA.1, BA.2, BA.4 and BA.5 subvariants). (bvsalud.org)
  • BACKGROUND: COVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern. (bvsalud.org)
  • Once it was clear that the effectiveness of the first generation of vaccines waned over time, and variants challenged them as well, interest in intranasal vaccines grew. (plos.org)
  • This will also show whether the new vaccine creates strong immunological 'memory' which can then be 'recalled' quickly by a further vaccination. (ox.ac.uk)
  • FDA announces 2 deaths of Pfizer vaccine trial participants from 'serious adverse events. (politifact.com)
  • The FDA describes the deaths of vaccine trial participants as serious adverse events, it didn't say that two participants died from serious adverse events. (politifact.com)
  • The story goes on to say that "a newly released document on the FDA website shows that 2 participants died as a result of 'serious adverse events' from the experimental Covid vaccine. (politifact.com)
  • According to the document, only three serious adverse events were determined by an investigator to be related to the vaccine or how the vaccine was administered: a shoulder injury, an irregular heartbeat, and swollen lymph nodes. (politifact.com)
  • The blog post says that the FDA announced that two Pfizer vaccine trial participants had died from serious adverse events. (politifact.com)
  • The case of Augusto Roux in Argentina suggests that in at least one instance, a trial participant whose symptoms were determined to be connected to the COVID-19 vaccine was later listed, in official records, as having experienced adverse events that were not related to the vaccination. (blacklistednews.com)
  • Many of these adverse events were indicated as being "unrelated" to the vaccines - even in instances where the patients were healthy or otherwise had no prior medical history related to the injuries they sustained. (blacklistednews.com)
  • 108 (0·9%) of 12 282 participants in the ChAdOx1 nCoV-19 group and 127 (1·1%) of 11 962 participants in the control group had serious adverse events. (bris.ac.uk)
  • Known allergy to components of influenza and MMR vaccines or serious adverse events to previous administration. (who.int)
  • Another Ebola vaccine, developed by NewLink Genetics, is also being tested in a human clinical trial. (livescience.com)
  • Participants will be compensated from £100 per day, with an average clinical trial length being 11 - 14 nights. (50connect.co.uk)
  • The BPL-1357 candidate influenza vaccine being tested in this clinical trial performed very well in pre-clinical studies and we look forward to learning how it performs in people. (nih.gov)
  • We estimated the VE against the Delta variant to be 82.8% (95% prediction interval: 68.7-96.0) using the mRNA vaccine platform, closely matching the reported VE of 83.0% from an observational study. (nature.com)
  • Among all participants from different geographies and including those infected with an emerging viral variant, Janssen's COVID-19 vaccine candidate was 66% effective overall in preventing moderate to severe COVID-19, 28 days after vaccination. (jnj.com)
  • People who have received two vaccine doses against COVID-19 have a lower, but still appreciable, risk of becoming infected with the delta variant compared with unvaccinated people. (medicalxpress.com)
  • Among household contacts who had received two vaccine doses, 25% (31/126 contacts) became infected with the delta variant compared with 38% (15/40) of unvaccinated household contacts. (medicalxpress.com)
  • Viral load declined more rapidly among vaccinated people infected with the delta variant (0.95 log10 virus copies/mL/day) compared with unvaccinated people with delta (0.79), alpha (0.82), or pre-alpha (0.69). (medicalxpress.com)
  • COVID-19 vaccines have been effective against the Delta variant. (news-medical.net)
  • The large number of trial participants in Argentina may be related to the fact that the trial appears to have been held simultaneously in 26 hospitals . (blacklistednews.com)
  • If it allows it to resume, regulators and scientists surely will be on the watch for similar symptoms in other trial participants. (thestkittsnevisobserver.com)
  • Dynavax), guidance on the use of hepatitis A vaccine for post-exposure prophylaxis and for infants prior to international travel, and a new framework to clarify ACIP review of evidence in developing recommendations. (immunize.org)
  • ACIP also approved the addition of LAIV to the Vaccines For Children (VFC) program for eligible children. (immunize.org)
  • 9vHPV in females and males, ACIP updated recommendations through manufacturer and government sponsored post- to include these vaccines. (cdc.gov)
  • In October 1988, CDC, in collaboration with the Health Care Financing Administration, awarded demonstration grant funds to nine programs to assess the cost-effectiveness of providing influenza vaccine to Medicare part B beneficiaries and measure the impact of Medicare coverage on promoting the vaccine as a routine preventive health measure. (cdc.gov)
  • Therefore, the development of a universal influenza virus vaccine is desirable. (scienceboard.net)
  • The vaccine consists of group 1 or group 2 stalk domains in combination with head domains from avian influenza virus subtypes. (scienceboard.net)
  • The individual steps in the test are the same for all these viruses, except that production and purification of viral and control antigens used in the assay are different for individual viruses. (cdc.gov)
  • STOP (SHERLOCK testing in one pot) is a streamlined assay that combines simplified extraction of viral RNA with isothermal amplification and CRISPR-mediated detection. (cdc.gov)
  • About 5,800 volunteers were enrolled, half getting the active vaccine. (blacklistednews.com)
  • Nine out of the 25 developed tenderness where the shot was given, and 10 volunteers reported tiredness, nausea or headaches after the vaccine. (npr.org)
  • The military are being enlisted to distribute vaccine vials on dry ice - in their "biggest task since the war " - and St John's Ambulance Volunteers are recruiting volunteers to administer the jab. (bmj.com)
  • Researchers will administer the vaccine candidate in up to 100 healthy volunteers between 18 and 55 years old, reports Ed Cara for Gizmodo . (smithsonianmag.com)
  • We are pleased to have with us today Lieutenant Commander Sarah Oliver, the co-lead for the Advisory Committee for Immunization Practices, COVID-19 Vaccines Work Group as part of CDC's COVID-19 response. (cdc.gov)
  • He acknowledged the deep involvement of the WHO Regional Director for the Eastern Mediterranean in polio eradication and his endless support to routine immunization and polio eradication as well as his efforts to achieve self sufficiency in vaccine production. (who.int)
  • According to WHO, a minimum of three doses of polio vaccine, either by oral or injected route, are required for effective immunization. (who.int)
  • COVID-19 fully vaccinated, or whose vaccination status was unknown vaccine breakthrough cases were those in fully vaccinated (median = 22.77 and 21.54, respectively). (cdc.gov)
  • For the study, participants completed online surveys regarding COVID-19 viral history and vaccination status. (northwestern.edu)
  • Targeting Protein protein Interactions for HIV Therapeutics New HIV drugs are being developed that target interactions between viral and cellular proteins. (medscape.com)
  • Joining forces to accelerate the development, production and equitable access to COVID-19 vaccines, diagnostics and therapeutics - on-line pledging event. (dissidentvoice.org)
  • Participants received intramuscular Ad26.ZEBOV followed by MVA-BN-Filo at 28-, 56-, or 84-day intervals, or saline. (plos.org)
  • Time intervals of potential exposure, based on the intervals between serologic and viral testing, were further analyzed for physicians/APPs and nurses by whether the individual participated in intubations or cardiac arrest care (i.e., potential aerosol-generating procedures) of patients, inclusive of those with confirmed or suspected COVID-19. (cdc.gov)